Rezolute Reports Phase 2b Proof of Concept for Rezpegaldesleukin in Severe Alopecia Areata

Rezolute, Inc. (Nasdaq: NKTR) announced positive results from its Phase 2b clinical study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, establishing clinical proof of concept for the investigational therapy in this autoimmune hair-loss condition.

The data support rezpegaldesleukin’s potential to address immune dysregulation underlying alopecia areata and provide a foundation for further clinical development.

Study Results Highlight Clinical Activity

The Phase 2b trial evaluated multiple dosing regimens of rezpegaldesleukin, an engineered interleukin-2 (IL-2) pathway agonist designed to selectively expand regulatory T cells. According to the company, treated patients demonstrated clinically meaningful improvements compared with baseline, supporting the therapy’s intended immune-modulating mechanism.

The study also provided important dose-response and safety insights that may help guide future trial design.

Mechanism Targets Underlying Autoimmune Drivers

Rezpegaldesleukin is designed to restore immune balance by increasing regulatory T cells without broadly activating pro-inflammatory immune responses. In alopecia areata, loss of immune tolerance leads to hair follicle attack, making immune modulation a key therapeutic strategy.

Management believes the Phase 2b results reinforce the rationale for targeting the IL-2 pathway in autoimmune diseases beyond Rezolute’s existing development programs.

Strategic Implications for Rezolute’s Pipeline

From a strategic perspective, the proof-of-concept data expand rezpegaldesleukin’s potential beyond its current focus areas and highlight optionality within the company’s immunology pipeline. Alopecia areata represents a large, underserved market with growing demand for disease-modifying therapies.

Positive mid-stage results may also support future partnering discussions or internal advancement into later-stage trials.

Investor Perspective and Next Steps

For investors, the Phase 2b outcome represents a clinical validation milestone, rather than a near-term commercialization event. Key next steps include further clinical development decisions, regulatory alignment, and potential advancement into Phase 3 studies.

Investors should continue to monitor trial progression, safety consistency across doses, and management’s strategy for prioritizing pipeline assets as Rezolute balances development focus and capital allocation.